$IVZ
Invesco Ltd Stock $ivz

$ivz Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000091420824000276 Filed on May 01, 2024

Income Statement

Concept	2024 Q1
Revenue	$1.475B
YoY Change	4.03%
Cost Of Revenue	$504.0M
YoY Change	10.74%
Gross Profit	$971.3M
YoY Change	0.85%
Gross Profit Margin	65.84%
Selling, General & Admin	$746.9M
YoY Change	641.71%
% of Gross Profit	76.9%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$11.30M
YoY Change	-75.85%
% of Gross Profit	1.16%
Operating Expenses	$758.2M
YoY Change	-37.27%
Operating Profit	$213.1M
YoY Change	1.72%
Interest Expense	$3.400M
YoY Change	-81.11%
% of Operating Profit	1.6%
Other Income/Expense, Net	$66.40M
YoY Change	142.34%
Pretax Income	$282.9M
YoY Change	20.03%
Income Tax	$68.70M
% Of Pretax Income	24.28%
Net Earnings	$141.5M
YoY Change	-2.41%
Net Earnings / Revenue	9.59%
Basic Earnings Per Share	$0.31
Diluted Earnings Per Share	$0.31
COMMON SHARES
Basic Shares Outstanding	449.2M shares
Diluted Shares Outstanding	453.5M shares

Balance Sheet

Concept	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$895.7M
YoY Change	0.75%
Cash & Equivalents	$895.7M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$708.3M
Other Receivables	$0.00
Total Short-Term Assets	$895.7M
YoY Change	-47.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$583.6M
YoY Change	1.92%
Goodwill	$8.621B
YoY Change	0.21%
Intangibles	$5.832B
YoY Change	-18.21%
Long-Term Investments	$10.08B
YoY Change	1432.37%
Other Assets
YoY Change
Total Long-Term Assets	$27.18B
YoY Change	-3.06%
TOTAL ASSETS
Total Short-Term Assets	$895.7M
Total Long-Term Assets	$27.18B
Total Assets	$28.08B
YoY Change	-5.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.321B
YoY Change	-9.86%
Accrued Expenses	$452.5M
YoY Change	4.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.774B
YoY Change	-30.42%
LONG-TERM LIABILITIES
Long-Term Debt	$8.628B
YoY Change	4.42%
Other Long-Term Liabilities	$3.597B
YoY Change	754.68%
Total Long-Term Liabilities	$12.22B
YoY Change	40.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.774B
Total Long-Term Liabilities	$12.22B
Total Liabilities	$13.52B
YoY Change	4.63%
SHAREHOLDERS EQUITY
Retained Earnings	$6.878B
YoY Change	-9.23%
Common Stock	$7.428B
YoY Change	-1.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.864B
YoY Change	-0.82%
Treasury Stock Shares
Shareholders Equity	$14.55B
YoY Change
Total Liabilities & Shareholders Equity	$28.08B
YoY Change	-5.57%

Cashflow Statement

Concept	2024 Q1
OPERATING ACTIVITIES
Net Income	$141.5M
YoY Change	-2.41%
Depreciation, Depletion And Amortization	$11.30M
YoY Change	-75.85%
Cash From Operating Activities	-$54.40M
YoY Change	-44.99%
INVESTING ACTIVITIES
Capital Expenditures	$21.00M
YoY Change	-44.88%
Acquisitions
YoY Change
Other Investing Activities	-$266.3M
YoY Change	-418.54%
Cash From Investing Activities	-$287.3M
YoY Change	-731.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$148.3M
YoY Change	-16.92%
NET CHANGE
Cash From Operating Activities	-$54.40M
Cash From Investing Activities	-$287.3M
Cash From Financing Activities	-$148.3M
Net Change In Cash	-$490.0M
YoY Change	111.3%
FREE CASH FLOW
Cash From Operating Activities	-$54.40M
Capital Expenditures	$21.00M
Free Cash Flow	-$75.40M
YoY Change	-44.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4000000	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1475300000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1418200000	usd
CY2024Q1	ivz	Third Party Distribution Service And Advisory ThirdPartyDistributionServiceAndAdvisory	504000000.0	usd
CY2023Q1	ivz	Third Party Distribution Service And Advisory ThirdPartyDistributionServiceAndAdvisory	455100000	usd
CY2024Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	472700000	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	462800000	usd
CY2024Q1	us-gaap	Marketing Expense MarketingExpense	18100000	usd
CY2023Q1	us-gaap	Marketing Expense MarketingExpense	19600000	usd
CY2024Q1	us-gaap	Communications Information Technology And Occupancy CommunicationsInformationTechnologyAndOccupancy	117600000	usd
CY2023Q1	us-gaap	Communications Information Technology And Occupancy CommunicationsInformationTechnologyAndOccupancy	110500000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	138500000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	105000000.0	usd
CY2024Q1	ivz	Total Transaction And Integration Charges TotalTransactionAndIntegrationCharges	0	usd
CY2023Q1	ivz	Total Transaction And Integration Charges TotalTransactionAndIntegrationCharges	41600000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11300000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14100000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1262200000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1208700000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	213100000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	209500000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6900000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	26100000	usd
CY2024Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	12400000	usd
CY2023Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	8600000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	15900000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	18000000.0	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35900000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	27400000	usd
CY2024Q1	ivz	Other Nonoperating Income Expense Consolidated Investment Products OtherNonoperatingIncomeExpenseConsolidatedInvestmentProducts	30500000	usd
CY2023Q1	ivz	Other Nonoperating Income Expense Consolidated Investment Products OtherNonoperatingIncomeExpenseConsolidatedInvestmentProducts	-17900000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	282900000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	235700000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68700000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69900000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	214200000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	165800000	usd
CY2024Q1	ivz	Proceeds From Sale Of Investments By Consolidated Investment Products ProceedsFromSaleOfInvestmentsByConsolidatedInvestmentProducts	237700000	usd
CY2023Q1	ivz	Proceeds From Sale Of Investments By Consolidated Investment Products ProceedsFromSaleOfInvestmentsByConsolidatedInvestmentProducts	669500000	usd
CY2024Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	36500000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13500000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38400000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	59200000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	59200000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	141500000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	145000000.0	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2024Q1	us-gaap	Profit Loss ProfitLoss	214200000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	165800000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	55100000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	4400000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-95300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	59500000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	118900000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	225300000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13500000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38400000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	59200000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	59200000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	46200000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	204500000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	214200000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	165800000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45100000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	46800000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	21100000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	37800000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	35300000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	27400000	usd
CY2024Q1	ivz	Gains And Losses Of Consolidated Investment Products Net GainsAndLossesOfConsolidatedInvestmentProductsNet	-2400000	usd
CY2023Q1	ivz	Gains And Losses Of Consolidated Investment Products Net GainsAndLossesOfConsolidatedInvestmentProductsNet	-63200000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6900000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	26100000	usd
CY2024Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	15900000	usd
CY2023Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	2700000	usd
CY2024Q1	ivz	Purchasesaleofinvestmentsby Ci Pnet PurchasesaleofinvestmentsbyCIPnet	3400000	usd
CY2023Q1	ivz	Purchasesaleofinvestmentsby Ci Pnet PurchasesaleofinvestmentsbyCIPnet	-32700000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-16800000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-2900000	usd
CY2024Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-365100000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	70700000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-689400000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-326600000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54400000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98900000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000000.0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38100000	usd
CY2024Q1	ivz	Purchase Of Investments By Consolidated Investment Products PurchaseOfInvestmentsByConsolidatedInvestmentProducts	472800000	usd
CY2023Q1	ivz	Purchase Of Investments By Consolidated Investment Products PurchaseOfInvestmentsByConsolidatedInvestmentProducts	562600000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	40700000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	100000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	21000000.0	usd
CY2024Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	6900000	usd
CY2023Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	7000000.0	usd
CY2024Q1	ivz	Proceeds From Payments To Consolidation And Deconsolidation Of Subsidiaries ProceedsFromPaymentsToConsolidationAndDeconsolidationOfSubsidiaries	-1700000	usd
CY2023Q1	ivz	Proceeds From Payments To Consolidation And Deconsolidation Of Subsidiaries ProceedsFromPaymentsToConsolidationAndDeconsolidationOfSubsidiaries	-10600000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-287300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45500000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	20400000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	27700000	usd
CY2024Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59200000	usd
CY2023Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59200000	usd
CY2024Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	90200000	usd
CY2023Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	85700000	usd
CY2024Q1	ivz	Capital Invested Into Consolidated Investment Products CapitalInvestedIntoConsolidatedInvestmentProducts	98300000	usd
CY2023Q1	ivz	Capital Invested Into Consolidated Investment Products CapitalInvestedIntoConsolidatedInvestmentProducts	27500000	usd
CY2024Q1	ivz	Capital Distributed By Consolidated Investment Products CapitalDistributedByConsolidatedInvestmentProducts	42600000	usd
CY2023Q1	ivz	Capital Distributed By Consolidated Investment Products CapitalDistributedByConsolidatedInvestmentProducts	67900000	usd
CY2024Q1	ivz	Proceedsfrom Debt Consolidated Investment Products ProceedsfromDebtConsolidatedInvestmentProducts	274300000	usd
CY2023Q1	ivz	Proceedsfrom Debt Consolidated Investment Products ProceedsfromDebtConsolidatedInvestmentProducts	39700000	usd
CY2024Q1	ivz	Repayments Of Consolidated Investment Products RepaymentsOfConsolidatedInvestmentProducts	76100000	usd
CY2023Q1	ivz	Repayments Of Consolidated Investment Products RepaymentsOfConsolidatedInvestmentProducts	5200000	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1030400000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2024Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	662800000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2024Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	600000000.0	usd
CY2023Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-148300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-178500000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-490000000.0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-231900000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14100000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11700000	usd
CY2024Q1	ivz	Effectof Exchange Rateon Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Cip EffectofExchangeRateonCashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCIP	-2000000.0	usd
CY2023Q1	ivz	Effectof Exchange Rateon Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Cip EffectofExchangeRateonCashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCIP	1000000.0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1931600000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1434100000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1425500000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1214900000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	895700000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	889000000.0	usd
CY2024Q1	ivz	Cash And Cash Equivalents Of Consolidated Investment Products CashAndCashEquivalentsOfConsolidatedInvestmentProducts	529800000	usd
CY2023Q1	ivz	Cash And Cash Equivalents Of Consolidated Investment Products CashAndCashEquivalentsOfConsolidatedInvestmentProducts	325900000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1425500000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1214900000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15170300000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	745700000	usd
CY2024Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	238600000	usd
CY2024Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-24400000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-95300000	usd
CY2024Q1	ivz	Change In Noncontrolling Interests In Consolidated Entities Net ChangeInNoncontrollingInterestsInConsolidatedEntitiesNet	-19600000	usd
CY2024Q1	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-53500000	usd
CY2024Q1	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	14.75
CY2024Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	59200000	usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.20
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	90200000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21100000	usd
CY2024Q1	ivz	Vested Shares VestedShares	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	500000	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	20400000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15185000000	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	667800000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15843500000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	998700000	usd
CY2023Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	179400000	usd
CY2023Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-13600000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	59500000	usd
CY2023Q1	ivz	Change In Noncontrolling Interests In Consolidated Entities Net ChangeInNoncontrollingInterestsInConsolidatedEntitiesNet	17900000	usd
CY2023Q1	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-105500000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	14.75
CY2023Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	59200000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.1875
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	85700000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37800000	usd
CY2023Q1	ivz	Vested Shares VestedShares	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	500000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27700000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15930200000	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	879600000	usd
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the quarter ended March 31, 2024, expenses for client-related travel and entertainment and outsourced services were reclassified to General and administrative expenses. The impact of this reclassification on the Consolidated Statements of Income is as follows:</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">• For the three months ended March 31, 2024: decreased Marketing and Property, office and technology expenses by $6.7 million and $23.6 million, respectively, and increased General and administrative by $30.3 million.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">• For the three months ended March 31, 2023: decreased Marketing and Property, office and technology expenses by $5.4 million and $23.9 million, respectively, and increased General and administrative by $29.3 million.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reclassification had no impact on our reported Operating revenues, Operating income, Net income, or any internal performance measure on which management is compensated.</span></div>
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	631800000	usd
CY2024Q1	us-gaap	Other Investments OtherInvestments	14900000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	14900000	usd
CY2024Q1	us-gaap	Investments Investments	963500000	usd
CY2023Q4	us-gaap	Investments Investments	919100000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16200000	usd
CY2024Q1	us-gaap	Derivative Assets DerivativeAssets	8100000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	740000000.0	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1300000	usd
CY2023Q4	us-gaap	Separate Account Assets SeparateAccountAssets	393900000	usd
CY2023Q4	us-gaap	Derivative Assets DerivativeAssets	4900000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1599000000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1300000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	651400000	usd
CY2024Q1	us-gaap	Other Investments OtherInvestments	14900000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	631800000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	14900000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	651400000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	6700000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4000000.0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4000000.0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4000000.0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4000000.0	shares
CY2024Q1	ivz	Lock Up Term LockUpTerm	P5Y
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	566100000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	566100000	shares
CY2024Q1	ivz	Treasury Stock Shares For Which Dividendand Voting Rights Do Not Apply TreasuryStockSharesForWhichDividendandVotingRightsDoNotApply	116300000	shares
CY2023Q4	ivz	Treasury Stock Shares For Which Dividendand Voting Rights Do Not Apply TreasuryStockSharesForWhichDividendandVotingRightsDoNotApply	116600000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	449800000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	449500000	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-96300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	55100000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	1000000.0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	4400000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-95300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	59500000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-95300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	59500000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1475300000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1418200000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	21100000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	37800000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18.84
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.13
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	18.21
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	18.29
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	17.41
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	67000000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	87300000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.13
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.74
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	182500000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M8D
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	141500000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	145000000.0	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	453200000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	458100000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	300000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	800000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	453500000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	458900000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2024Q1	ivz	Undrawn Capital Commitments UndrawnCapitalCommitments	664600000	usd
CY2023Q4	ivz	Undrawn Capital Commitments UndrawnCapitalCommitments	623300000	usd
CY2024Q1	ivz	Net Interests In Consolidated Investment Products NetInterestsInConsolidatedInvestmentProducts	521900000	usd
CY2023Q4	ivz	Net Interests In Consolidated Investment Products NetInterestsInConsolidatedInvestmentProducts	546200000	usd
CY2024Q1	ivz	Variable Interest Entity Reporting Entity Involvement Unfunded Capital Commitments Amount VariableInterestEntityReportingEntityInvolvementUnfundedCapitalCommitmentsAmount	153200000	usd
CY2023Q4	ivz	Variable Interest Entity Reporting Entity Involvement Unfunded Capital Commitments Amount VariableInterestEntityReportingEntityInvolvementUnfundedCapitalCommitmentsAmount	142500000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	4000000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000914208-24-000276-index-headers.html	Edgar Link	pending
0000914208-24-000276-index.html	Edgar Link	pending
0000914208-24-000276.txt	Edgar Link	pending
0000914208-24-000276-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_02.jpg	Edgar Link	pending
ivz-20240331.htm	Edgar Link	pending
ivz-20240331.xsd	Edgar Link	pending
ivz-20240331_g1.jpg	Edgar Link	pending
ivz1q2024ex101.htm	Edgar Link	pending
ivz1q2024ex102.htm	Edgar Link	pending
ivz1q2024ex103.htm	Edgar Link	pending
ivz1q2024ex104.htm	Edgar Link	pending
ivz1q2024ex311.htm	Edgar Link	pending
ivz1q2024ex312.htm	Edgar Link	pending
ivz-20240331_cal.xml	Edgar Link	unprocessable
ivz-20240331_def.xml	Edgar Link	unprocessable
ivz-20240331_lab.xml	Edgar Link	unprocessable
ivz-20240331_pre.xml	Edgar Link	unprocessable
ivz-20240331_htm.xml	Edgar Link	completed
ivz1q2024ex321.htm	Edgar Link	pending
ivz1q2024ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IVZ
Invesco Ltd Stock $ivz

2024 Q1 Form 10-Q Financial Statement

#000091420824000276 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVZ Invesco Ltd Stock $ivz

2024 Q1 Form 10-Q Financial Statement

#000091420824000276 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVZ
Invesco Ltd Stock $ivz